Latest news with #FiveForces
Yahoo
3 days ago
- Business
- Yahoo
$101.5 Bn Oncology Diagnostics Global Markets, 2023-2024 & 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche., Danaher, Agilent Technologies, Siemens Healthineers, and GE HealthCare
The global oncology diagnostics market is projected to grow from $77.6 billion in 2024 to $101.5 billion by 2029. Key growth drivers include rising cancer rates, R&D, new product launches, and expansion in emerging markets. This comprehensive report covers market segments, regional insights, and profiles of major players like Roche and Siemens. Oncology Diagnostics Market Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Oncology Diagnostics: Global Markets" report has been added to global market for oncology diagnostics is estimated to increase from $77.6 billion in 2024 to reach $101.5 billion by 2029, at a compound annual growth rate (CAGR) of 5.5% from 2024 through 2029. The base year for the study is 2023, 2024 is the estimated year, with projections through 2029, including compound annual growth rates (CAGRs) for the forecast period. This report analyzes the oncology diagnostics market and the competitive landscape. The profiles of several leading companies, including their revenues, product portfolios and recent activities are also examined. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and oncology diagnostics market is growing at a steady rate driven by the increasing incidence and the prevalence of a wide range of cancers globally, R&D and new product launches by the major players in the market, strategic initiatives by the major players, and increasing numbers of private diagnostic centers in emerging markets. Key Attributes: Report Attribute Details No. of Pages 192 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $77.6 Billion Forecasted Market Value (USD) by 2029 $101.5 Billion Compound Annual Growth Rate 5.5% Regions Covered Global The report includes: 94 data tables and 59 additional tables Analyses of global market trends for oncology diagnostics, with market revenue data from 2021 to 2024, forecasts and projected CAGRs through 2029 Estimates of the size and growth of the global market, and a corresponding market share analysis by product type, application, end user, and region Facts and figures pertaining to the major market dynamics, opportunities and challenges, emerging technologies, regulations, and impacts of macroeconomic variables Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses Coverage of treatments in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends Evaluation of recent patent activity featuring key granted and published patents Insights into oncology therapeutics research activity, emerging technologies, clinical trials and pipeline products Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Danaher Corp., Agilent Technologies Inc., Siemens Healthineers AG, and GE HealthCare Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics and Growth Factors Emerging Technologies Segmental Analysis Regional Analysis Strategic Initiatives Conclusion Chapter 2 Market Overview Overview Macroeconomic Factors Analysis Impact of the U.S.-China Trade War Porter's Five Forces Analysis in the Oncology Market Chapter 3 Market Dynamics Key Takeaways Market Drivers Rising Incidence of Cancer Cases Demand for Earlier Intervention and Preventive Diagnostic Screening Growing Adoption of Companion Diagnostics Increasing Aging Population Worldwide Market Opportunities Expanding Cancer Screening Enhancing Access to Advanced Technologies Market Restraints Complex Reimbursement Policies Lack of Cancer Awareness Cost of Oncology Diagnostic Tests Turnaround Time of Oncology Diagnostics Market Challenges Lack of Skilled Professionals Complex Sample Preparation and Handling Chapter 4 Regulatory Landscape Market Regulations, by Top Country/Region The U.S. Europe Japan China Chapter 5 Emerging Technologies and Developments Emerging Technologies AI in Oncology Diagnostics Multi-Cancer Early Detection (MCED) Theranostics Digital Pathology and AI Integration Patent Analysis Key Takeaways Chapter 6 Oncology Diagnostics Market Segment Breakdown Global Market Insights Market Breakdown by Product Type Diagnostics Imaging Endoscopy Devices Tumor Biomarker Tests Biopsy Devices Hematoxylin and Eosin Immunohistochemistry In situ Hybridization Polymerase Chain Reaction Next-Generation Sequencing Others Market Breakdown by Application Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Gastric Cancer Other Applications Market Breakdown by End User Hospitals, Cancer Centers and Clinics Diagnostic Imaging and Reference Laboratories Others Geographic Breakdown Market Breakdown, by Region Key Takeaways North America Europe Asia-Pacific South America Middle East and Africa (MEA) Chapter 7 Competitive Intelligence Company Share Analysis Strategic Initiatives Chapter 8 Sustainability in the Market for Oncology Diagnostics: An ESG Perspective Introduction to ESG ESG Performance Analysis Environmental Performance Social Performance Governance Performance Concluding Remarks Chapter 9 Appendix Research Methodology References Abbreviations Company Profiles ABBOTT AGILENT TECHNOLOGIES INC. BD BIOMERIEUX BIO-RAD LABORATORIES INC. DANAHER CORP. F. HOFFMANN-LA ROCHE LTD. GE HEALTHCARE ILLUMINA INC. KONINKLIJKE PHILIPS N.V. MERCK KGAA MYRIAD GENETICS INC. QIAGEN SIEMENS HEALTHINEERS AG THERMO FISHER SCIENTIFIC INC. ZYTOVISION GMBH Other Emerging Players in the Oncology Diagnostics Market List of TablesSummary Table: Global Market for Oncology Diagnostics, by Product Type, Through 2029Table 1: Global Incidence of All Cancer Cases, by WHO Region, 2022-2045Table 2: Global Incidence of Cancer Cases, Both Sexes, by Cancer Type, 2022Table 3: Cancer Treatments Based on Specific TestsTable 4: Select FDA-Approved AI-Associated/Associable-Equipped Medical DevicesTable 5: Selected Patent Grants in Oncology Diagnostics, 2023-2025Table 6: Global Oncology Diagnostics Market, by Product Type, Through 2029Table 7: Global Diagnostics Imaging Market, by Region, Through 2029Table 8: Global Endoscopy Market, by Region, Through 2029Table 9: Global Tumor Biomarker Tests Market, by Region, Through 2029Table 10: Global Biopsy Devices Market, by Region, Through 2029Table 11: Global H&E and Special Stains Diagnostics Market, by Region, Through 2029Table 12: Global IHC Oncology Diagnostics Market, by Region, Through 2029Table 13: Global ISH Oncology Diagnostics Market, by Region, Through 2029Table 14: Global PCR Oncology Diagnostics Market, by Region, Through 2029Table 15: Global NGS Oncology Diagnostics Market, by Region, Through 2029Table 16: Global Other Oncology Diagnostics Tests Market, by Region, Through 2029Table 17: Global Oncology Diagnostics Market, by Application, Through 2029Table 18: Global Breast Cancer Diagnostics Market, by Region, Through 2029Table 19: Global Lung Cancer Diagnostics Market, by Region, Through 2029Table 20: Global Colorectal Cancer Diagnostics Market, by Region, Through 2029Table 21: Global Prostate Cancer Diagnostics Market, by Region, Through 2029Table 22: Global Gastric Cancer Diagnostics Market, by Region, Through 2029Table 23: Global Oncology Diagnostics Market in Other Cancer Applications, by Region, Through 2029Table 24: Global Oncology Diagnostics Market, by End User, Through 2029Table 25: Global Oncology Diagnostics Market in Hospitals, Cancer Centers and Clinics, Through 2029Table 26: Global Oncology Diagnostics Market in Diagnostic Imaging and Reference Laboratories, Through 2029Table 27: Global Oncology Diagnostics Market in Other End Uses, Through 2029Table 28: Global Oncology Diagnostics Market, by Region, Through 2029Table 29: North American Oncology Diagnostics Market, by Country, Through 2029Table 30: U.S. Oncology Diagnostics Market, by Product Type, Through 2029Table 31: U.S. Oncology Diagnostics Market, by Application, Through 2029Table 32: U.S. Oncology Diagnostics Market, by End User, Through 2029Table 33: Canadian Oncology Diagnostics Market, by Product Type, Through 2029Table 34: Canadian Oncology Diagnostics Market, by Application, Through 2029Table 35: Canadian Oncology Diagnostics Market, by End User, Through 2029Table 36: Mexican Oncology Diagnostics Market, by Product Type, Through 2029Table 37: Mexican Oncology Diagnostics Market, by Application, Through 2029Table 38: Mexican Oncology Diagnostics Market, by End User, Through 2029Table 39: European Oncology Diagnostics Market, by Country, Through 2029Table 40: Cancer Incidence and Mortality Numbers in Germany, Both Sexes, 2022Table 41: German Oncology Diagnostics Market, by Product Type, Through 2029Table 42: German Oncology Diagnostics Market, by Application, Through 2029Table 43: German Oncology Diagnostics Market, by End User, Through 2029Table 44: Cancer Incidence and Mortality Numbers in France, Both Sexes, 2022Table 45: French Oncology Diagnostics Market, by Product Type, Through 2029Table 46: French Oncology Diagnostics Market, by Application, Through 2029Table 47: French Oncology Diagnostics Market, by End User, Through 2029Table 48: New Cases of Cancer Diagnosed Each Year in the U.K., 2021Table 49: The U.K. Oncology Diagnostics Market, by Product Type, Through 2029Table 50: The U.K. Oncology Diagnostics Market, by Application, Through 2029Table 51: The U.K. Oncology Diagnostics Market, by End User, Through 2029Table 52: Cancer Incidence and Mortality Numbers in Italy, Both Sexes, 2022Table 53: Italian Oncology Diagnostics Market, by Product Type, Through 2029Table 54: Italian Oncology Diagnostics Market, by Application, Through 2029Table 55: Italian Oncology Diagnostics Market, by End User, Through 2029Table 56: Cancer Incidence and Mortality Numbers in Spain, Both Sexes, 2022Table 57: Spanish Oncology Diagnostics Market, by Product Type, Through 2029Table 58: Spanish Oncology Diagnostics Market, by Application, Through 2029Table 59: Spanish Oncology Diagnostics Market, by End User, Through 2029Table 60: Rest of European Countries' Oncology Diagnostics Market, by Product Type, Through 2029Table 61: Rest of European Countries' Oncology Diagnostics Market, by Application, Through 2029Table 62: Rest of European Countries' Oncology Diagnostics Market, by End User, Through 2029Table 63: Asia-Pacific Oncology Diagnostics Market, by Country, Through 2029Table 64: Cancer Incidence and Mortality Numbers in China, Both Sexes, 2022Table 65: Chinese Oncology Diagnostics Market, by Product Type, Through 2029Table 66: Chinese Oncology Diagnostics Market, by Application, Through 2029Table 67: Chinese Oncology Diagnostics Market, by End User, Through 2029Table 68: Cancer Incidence and Mortality Numbers in Japan, Both Sexes, 2022Table 69: Japanese Oncology Diagnostics Market, by Product Type, Through 2029Table 70: Japanese Oncology Diagnostics Market, by Application, Through 2029Table 71: Japanese Oncology Diagnostics Market, by End User, Through 2029Table 72: Cancer Incidence and Mortality Numbers in India, Both Sexes, 2022Table 73: Indian Oncology Diagnostics Market, by Product Type, Through 2029Table 74: Indian Oncology Diagnostics Market, by Application, Through 2029Table 75: Indian Oncology Diagnostics Market, by End User, Through 2029Table 76: Rest of Asia-Pacific Oncology Diagnostics Market, by Product Type, Through 2029Table 77: Rest of Asia-Pacific Oncology Diagnostics Market, by Application, Through 2029Table 78: Rest of Asia-Pacific Oncology Diagnostics Market, by End User, Through 2029Table 79: South American Oncology Diagnostics Market, by Country, Through 2029Table 80: Brazilian Oncology Diagnostics Market, by Product Type, Through 2029Table 81: Brazilian Oncology Diagnostics Market, by Application, Through 2029Table 82: Brazilian Oncology Diagnostics Market, by End User, Through 2029Table 83: Argentine Oncology Diagnostics Market, by Product Type, Through 2029Table 84: Argentine Oncology Diagnostics Market, by Application, Through 2029Table 85: Argentine Oncology Diagnostics Market, by End User, Through 2029Table 86: Rest of South American Oncology Diagnostics Market, by Product Type, Through 2029Table 87: Rest of South American Oncology Diagnostics Market, by Application, Through 2029Table 88: Rest of South American Oncology Diagnostics Market, by End User, Through 2029Table 89: Middle East and African Oncology Diagnostics Market, by Product Type, Through 2029Table 90: Middle East and African Oncology Diagnostics Market, by Application, Through 2029Table 91: Middle East and African Oncology Diagnostics Market, by End User, Through 2029Table 92: Company Shares in the Oncology Diagnostics Market, 2023Table 93: ESG: Environmental OverviewTable 94: ESG: Social OverviewTable 95: ESG: Governance OverviewTable 96: Abbreviations Used in this ReportTable 97: Abbott: Company SnapshotTable 98: Abbott: Financial Performance, FY 2022 and 2023Table 99: Abbott: Product PortfolioTable 100: Agilent Technologies Inc.: Company SnapshotTable 101: Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024Table 102: Agilent Technologies Inc.: Product PortfolioTable 103: Agilent Technologies Inc.: News/Key Developments, 2024Table 104: BD: Company SnapshotTable 105: BD: Financial Performance, FY 2023 and 2024Table 106: BD: Product PortfolioTable 107: bioMerieux: Company SnapshotTable 108: bioMerieux: Financial Performance, FY 2022 and 2023Table 109: bioMerieux: Product PortfolioTable 110: Bio-Rad Laboratories Inc.: Company SnapshotTable 111: Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024Table 112: Bio-Rad Laboratories Inc.: Product PortfolioTable 113: Danaher Corp.: Company SnapshotTable 114: Danaher Corp.: Financial Performance, FY 2022 and 2023Table 115: Danaher Corp.: Product PortfolioTable 116: Danaher Corp.: News/Key Developments, 2023Table 117: F. Hoffmann-La Roche Ltd.: Company SnapshotTable 118: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024Table 119: F. Hoffmann-La Roche Ltd.: Product PortfolioTable 120: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024 and 2025Table 121: GE HealthCare: Company SnapshotTable 122: GE HealthCare: Financial Performance, FY 2023 and 2024Table 123: GE HealthCare: Product PortfolioTable 124: GE HealthCare: News/Key Developments, 2024Table 125: Illumina Inc.: Company SnapshotTable 126: Illumina Inc.: Financial Performance, FY 2023 and 2024Table 127: Illumina Inc.: Product PortfolioTable 128: Illumina Inc.: News/Key Developments, 2024Table 129: Koninklijke Philips N.V.: Company SnapshotTable 130: Koninklijke Philips N.V.: Financial Performance, FY 2023 and 2024Table 131: Koninklijke Philips N.V.: Product PortfolioTable 132: Merck KGaA: Company SnapshotTable 133: Merck KGaA: Financial Performance, FY 2022 and 2023Table 134: Merck KGaA: Product PortfolioTable 135: Myriad Genetics Inc.: Company SnapshotTable 136: Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023Table 137: Myriad Genetics Inc.: Product PortfolioTable 138: Myriad Genetics Inc.: News/Key Developments, 2025Table 139: Qiagen: Company SnapshotTable 140: Qiagen: Financial Performance, FY 2022 and 2023Table 141: Qiagen: Product PortfolioTable 142: Siemens Healthineers AG: Company SnapshotTable 143: Siemens Healthineers AG: Financial Performance, FY 2023 and 2024Table 144: Siemens Healthineers AG: Product PortfolioTable 145: Siemens Healthineers AG: News/Key Developments, 2024Table 146: Thermo Fisher Scientific Inc.: Company SnapshotTable 147: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023Table 148: Thermo Fisher Scientific Inc.: Product PortfolioTable 149: Thermo Fisher Scientific Inc.: News/Key Developments, 2023Table 150: ZytoVision GmbH: Company SnapshotTable 151: ZytoVision GmbH: Product PortfolioTable 152: Emerging Startups in Oncology Diagnostics MarketList of FiguresSummary Figure: Global Market Shares of Oncology Diagnostics, by Product Type, 2023Figure 1: Porter's Five Forces Analysis of the Oncology MarketFigure 2: Market Dynamics of Oncology DiagnosticsFigure 3: Global Incidence Shares of All Cancer Cases, by Region, 2022Figure 4: Number of FDA-Approved Companion Diagnostic Devices, 1997-2024Figure 5: Emerging Trends and Technologies in Oncology DiagnosticsFigure 6: Share of Global Market for Oncology Diagnostics, by Product Type, 2023Figure 7: Share of Global Market for Oncology Diagnostics, by Application, 2023Figure 8: Shares of Global Market for Oncology Diagnostics, by End User, 2023Figure 9: Share of Global Market for Oncology Diagnostics, by Region, 2023Figure 10: Share of North American Market for Oncology Diagnostics, by Country, 2023Figure 11: Share of European Market for Oncology Diagnostics, by Country, 2023Figure 12: Breast Cancer Screening Rates in Europe, by Country, 2012 vs. 2022Figure 13: Cervical Cancer Screening Rates in European Countries, 2022Figure 14: Colorectal Cancer Screening Rates in European Countries, 2022Figure 15: Current and Forecasted Cancer Prevalence in the U.K., 2020-2040Figure 16: Shares of Cancer Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022Figure 17: Shares of All Cancer Mortality Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022Figure 18: Share of Asia-Pacific Market for Oncology Diagnostics, by Country, 2023Figure 19: Share of South American Market for Oncology Diagnostics, by Country, 2023Figure 20: Share of the Global Market for Oncology Diagnostics, by Company, 2023Figure 21: ESG PillarsFigure 22: Advantages of ESG for CompaniesFigure 23: Abbott: Revenue Share, by Business Unit, FY 2023Figure 24: Abbott: Revenue Share, by Country/Region, FY 2023Figure 25: Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024Figure 26: Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024Figure 27: BD: Revenue Share, by Business Unit, FY 2024Figure 28: BD: Revenue Share, by Country/Region, FY 2024Figure 29: bioMerieux: Revenue Share, by Business Unit, FY 2023Figure 30: bioMerieux: Revenue Share, by Region, FY 2023Figure 31: Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024Figure 32: Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024Figure 33: Danaher Corp.: Revenue Share, by Business Unit, FY 2023Figure 34: Danaher Corp.: Revenue Share, by Country/Region, FY 2023Figure 35: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024Figure 36: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024Figure 37: GE HealthCare: Revenue Share, by Business Unit, FY 2024Figure 38: GE HealthCare: Revenue Share, by Country/Region, FY 2024Figure 39: Illumina Inc.: Revenue Share, by Business Unit, FY 2024Figure 40: Illumina Inc.: Revenue Share, by Country/Region, FY 2024Figure 41: Koninklijke Philips N.V.: Revenue Share, by Business Unit, FY 2024Figure 42: Koninklijke Philips N.V.: Revenue Share, by Country/Region, FY 2023Figure 43: Merck KGaA: Market Share, by Business Unit, 2023Figure 44: Merck KGaA: Revenue Share, by Country/Region, 2023Figure 45: Myriad Genetics Inc.: Revenue Share, by Business Unit, 2023Figure 46: Myriad Genetics Inc.: Revenue Share, by Country/Region, 2023Figure 47: Qiagen: Revenue Share, by Business Unit, FY 2023Figure 48: Qiagen: Revenue Share, by Country/Region, FY 2023Figure 49: Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024Figure 50: Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024Figure 51: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023Figure 52: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023Companies Featured Abbott Agilent Technologies Inc. BD bioMerieux Bio-Rad Laboratories Inc. Danaher Corp. F. Hoffmann-La Roche Ltd. GE Healthcare Illumina Inc. Koninklijke Philips N.V. Merck KGaA Myriad Genetics Inc. QIAGEN Siemens Healthineers AG Thermo Fisher Scientific Inc. ZytoVision GmbH For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Oncology Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
3 days ago
- Health
- Yahoo
Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments
Global Influenza Market to Hit USD 12.8 Billion by 2029: A Comprehensive AnalysisThe global influenza market, valued at USD 9 billion in 2024, is anticipated to grow at a CAGR of 7.2%, reaching USD 12.8 billion by 2029. This growth is driven by the vaccine segment, the most effective preventive measure against influenza's severe effects. The report offers a thorough examination of market trends, including vaccines, diagnostics, and therapeutics, with insights into regional dynamics and competitive landscapes. Key players such as Danaher Corp., Sanofi, and Abbott are highlighted, alongside detailed analyses using Porter's Five Forces and PESTLE models. SEO keywords include global influenza market, influenza vaccines, diagnostics, and market growth. Influenza Market Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Influenza Market 2025" report has been added to Influenza Market was valued at USD 9 Billion in 2024, and is projected to reach USD 12.8 Billion by 2029, rising at a CAGR of 7.2%. The vaccines segment dominated the global influenza market in 2023. Because influenza vaccines are the most effective method for lowering the risk of contracting influenza and suffering its subsequent effects, the market for this segment is growing. Influenza comes in four varieties: A, B, C and D. Seasonal epidemics are caused by the infectious influenza A and B viruses. Most people recover from fever and other symptoms within a week without medical intervention. Nevertheless, influenza can result in fatalities or severe illness, particularly in high-risk populations. Seasonal influenza spreads quickly and easily in crowded places like schools and nursing homes, so receiving a vaccination as soon as possible is critical. Based on vaccine type, the segment is further subdivided into inactivated and liveattenuated market for influenza diagnostics has been segmented into rapid tests and conventional lab tests based on diagnostic type. Increased R&D efforts are being made to detect and diagnose influenza more accurately due to its increasing global prevalence. Research is focusing on developing quicker and more precise diagnostic tools for influenza viruses, which will expand the drugs approved for influenza treatments are discussed in the therapeutic segment. These medications may lessen the likelihood of complications, lessen the severity of symptoms and shorten the course of the illness. These drugs include oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) and baloxavir marboxil (Xofluza).Report ScopeThis report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions - North America, Europe and Asia-Pacific - and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through report includes: 55 data tables and 70 additional tables An updated overview and in-depth analysis of the global influenza market Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029 Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV) Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors Insight into the influenza industry structure, government regulations, and key development issues Analysis of the key patent grants and IP aspects A discussion of the industry's ESG challenges and practices of the industry Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott Key Attributes: Report Attribute Details No. of Pages 188 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $9 Billion Forecasted Market Value (USD) by 2029 $12.8 Billion Compound Annual Growth Rate 7.2% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview Pandemic Scenario Porter's Five Forces Analysis in the Influenza Vaccines Market Supply Chain Analysis Vaccine Development Vaccine Manufacturing Storage and Inventory Management Distribution Administration and Immunization Macroeconomic Factors Analysis Impact of U.S.-China Trade War Global Economic Growth Demographic Trends Public Health Crises and Pandemics Chapter 3 Market Dynamics Market Dynamics Key Takeaways Market Drivers Development of Rapid Tests and Molecular Technologies Government Support and Funding for Novel Therapies and Diagnosis Rising Public Awareness About Flu Vaccines Market Restraints Therapeutic Market Dominated by Limited Suppliers High Cost Associated with Storage and Supply of Flu Vaccines Market Opportunities Robust Pipeline of Influenza Vaccines Demand for Improved Prevention, Treatment and Vaccine Accessibility Chapter 4 Regulatory Landscape Overview Regulatory Aspects of Influenza Vaccines Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season Influenza Vaccines Approved by EMA Regulatory Scenario of Influenza Drugs Approval Process of Influenza Detection Kit Sensitivity Specificity Chapter 5 Emerging Trends and Pipeline Analysis Overview Advance in Influenza Diagnosis SHINE Technology Electrochemical Biosensors Wearable Lab-on-a-Chip Devices Quantum Dots and Fluorescent Nanoparticles Role of AI in Influenza Diagnosis Emerging Technologies in Influenza Vaccines Universal Influenza Vaccine mRNA-based Influenza Vaccines Nanotechnology-based Vaccines Patch-based Vaccines Advances in Influenza Therapeutics Nanoparticle-based Therapies Potential Drug Agents in Clinical Trials Patent Analysis Key Takeaways Chapter 6 Market Segmentation Analysis Segmentation Breakdown Global Influenza Market by Product Segment Influenza Diagnostics Influenza Vaccines Influenza Therapeutics Geographic Breakdown Key Takeaways North America Europe Asia-Pacific Rest of World Chapter 7 Competitive Intelligence Company Share Analysis of the Influenza Vaccines Market Company Share Analysis of Influenza Diagnostics Market Company Share Analysis of Influenza Therapeutics Market Venture Fundings and Investments Landscape Key Developments in Market Chapter 8 Sustainability in Influenza Market: ESG Perspective Overview ESG Risk Ratings Conclusion Chapter 9 AppendixCompanies Featured Abbott AstraZeneca BD Biocryst Pharmaceuticals Inc. CSL Daiichi Sankyo Co. Ltd. Danaher Corp. F. Hoffmann-La Roche Ltd. GSK PLC Hologic Inc. Quidelortho Corp. Sanofi Sekisui Diagnostics Thermo Fisher Scientific Inc. Viatris Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Influenza Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
3 days ago
- Health
- Yahoo
Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments
Global Influenza Market to Hit USD 12.8 Billion by 2029: A Comprehensive AnalysisThe global influenza market, valued at USD 9 billion in 2024, is anticipated to grow at a CAGR of 7.2%, reaching USD 12.8 billion by 2029. This growth is driven by the vaccine segment, the most effective preventive measure against influenza's severe effects. The report offers a thorough examination of market trends, including vaccines, diagnostics, and therapeutics, with insights into regional dynamics and competitive landscapes. Key players such as Danaher Corp., Sanofi, and Abbott are highlighted, alongside detailed analyses using Porter's Five Forces and PESTLE models. SEO keywords include global influenza market, influenza vaccines, diagnostics, and market growth. Influenza Market Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Influenza Market 2025" report has been added to Influenza Market was valued at USD 9 Billion in 2024, and is projected to reach USD 12.8 Billion by 2029, rising at a CAGR of 7.2%. The vaccines segment dominated the global influenza market in 2023. Because influenza vaccines are the most effective method for lowering the risk of contracting influenza and suffering its subsequent effects, the market for this segment is growing. Influenza comes in four varieties: A, B, C and D. Seasonal epidemics are caused by the infectious influenza A and B viruses. Most people recover from fever and other symptoms within a week without medical intervention. Nevertheless, influenza can result in fatalities or severe illness, particularly in high-risk populations. Seasonal influenza spreads quickly and easily in crowded places like schools and nursing homes, so receiving a vaccination as soon as possible is critical. Based on vaccine type, the segment is further subdivided into inactivated and liveattenuated market for influenza diagnostics has been segmented into rapid tests and conventional lab tests based on diagnostic type. Increased R&D efforts are being made to detect and diagnose influenza more accurately due to its increasing global prevalence. Research is focusing on developing quicker and more precise diagnostic tools for influenza viruses, which will expand the drugs approved for influenza treatments are discussed in the therapeutic segment. These medications may lessen the likelihood of complications, lessen the severity of symptoms and shorten the course of the illness. These drugs include oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) and baloxavir marboxil (Xofluza).Report ScopeThis report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions - North America, Europe and Asia-Pacific - and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through report includes: 55 data tables and 70 additional tables An updated overview and in-depth analysis of the global influenza market Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029 Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV) Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors Insight into the influenza industry structure, government regulations, and key development issues Analysis of the key patent grants and IP aspects A discussion of the industry's ESG challenges and practices of the industry Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott Key Attributes: Report Attribute Details No. of Pages 188 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $9 Billion Forecasted Market Value (USD) by 2029 $12.8 Billion Compound Annual Growth Rate 7.2% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview Pandemic Scenario Porter's Five Forces Analysis in the Influenza Vaccines Market Supply Chain Analysis Vaccine Development Vaccine Manufacturing Storage and Inventory Management Distribution Administration and Immunization Macroeconomic Factors Analysis Impact of U.S.-China Trade War Global Economic Growth Demographic Trends Public Health Crises and Pandemics Chapter 3 Market Dynamics Market Dynamics Key Takeaways Market Drivers Development of Rapid Tests and Molecular Technologies Government Support and Funding for Novel Therapies and Diagnosis Rising Public Awareness About Flu Vaccines Market Restraints Therapeutic Market Dominated by Limited Suppliers High Cost Associated with Storage and Supply of Flu Vaccines Market Opportunities Robust Pipeline of Influenza Vaccines Demand for Improved Prevention, Treatment and Vaccine Accessibility Chapter 4 Regulatory Landscape Overview Regulatory Aspects of Influenza Vaccines Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season Influenza Vaccines Approved by EMA Regulatory Scenario of Influenza Drugs Approval Process of Influenza Detection Kit Sensitivity Specificity Chapter 5 Emerging Trends and Pipeline Analysis Overview Advance in Influenza Diagnosis SHINE Technology Electrochemical Biosensors Wearable Lab-on-a-Chip Devices Quantum Dots and Fluorescent Nanoparticles Role of AI in Influenza Diagnosis Emerging Technologies in Influenza Vaccines Universal Influenza Vaccine mRNA-based Influenza Vaccines Nanotechnology-based Vaccines Patch-based Vaccines Advances in Influenza Therapeutics Nanoparticle-based Therapies Potential Drug Agents in Clinical Trials Patent Analysis Key Takeaways Chapter 6 Market Segmentation Analysis Segmentation Breakdown Global Influenza Market by Product Segment Influenza Diagnostics Influenza Vaccines Influenza Therapeutics Geographic Breakdown Key Takeaways North America Europe Asia-Pacific Rest of World Chapter 7 Competitive Intelligence Company Share Analysis of the Influenza Vaccines Market Company Share Analysis of Influenza Diagnostics Market Company Share Analysis of Influenza Therapeutics Market Venture Fundings and Investments Landscape Key Developments in Market Chapter 8 Sustainability in Influenza Market: ESG Perspective Overview ESG Risk Ratings Conclusion Chapter 9 AppendixCompanies Featured Abbott AstraZeneca BD Biocryst Pharmaceuticals Inc. CSL Daiichi Sankyo Co. Ltd. Danaher Corp. F. Hoffmann-La Roche Ltd. GSK PLC Hologic Inc. Quidelortho Corp. Sanofi Sekisui Diagnostics Thermo Fisher Scientific Inc. Viatris Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Influenza Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Fashion Value Chain
02-05-2025
- Business
- Fashion Value Chain
Indian Textile Industry's Management Model Response to US Tariffs
Ms. Ananya Tiwari, Post-Graduate Academic Scholar in Fashion Management, National Institute of Fashion Technology, Ministry of Textiles, Daman campus Dr Vidhu Sekhar P, Assistant Professor, Department of Fashion Management Studies, National Institute of Fashion Technology, Ministry of Textiles, Daman campus Abstract With the impending 2025 U.S. tariffs changing the dynamics of international trade, the Indian textile sector is once again in the news. To protect their companies, 3 significant Indian textile companies—Welspun Living, Gokaldas Exports, and Faze Three—are acting proactively and dynamically. This article examines the practical applications of textbook management models, such as Porter's Five Forces, Ansoff Matrix, and Risk Management, by these companies. This case provides a unique real-time illustration of operational resilience and strategic agility for management students. It sheds light on how companies apply theoretical frameworks to turn outside threats into expansion prospects. Keywords Strategic Management, Indian Textile Industry, Porter's Five Forces, Ansoff Matrix, Risk Mitigation, Global Trade, Textile Exports, Business Strategy. Introduction The fortunes of the textile industry have always been significantly influenced by global trade policies. Indian textile exporters face a more complicated environment as the United States increases tariffs in 2025. As a result, businesses are showing how fundamental management concepts, which are usually taught in business schools, have real-world applications. This article demonstrates how strategic models and frameworks can be useful tools for success and survival using the examples of five top businesses. Application of Porter's Five Forces Understanding the competitive forces operating within an industry is made easier with the aid of Michael Porter's Five Forces model. This model is being strategically used by Indian textile companies to reconsider their stances and lessen pressure. For example, by purchasing BRFL Textiles, Gokaldas Exports addressed supplier power, a significant issue in manufacturing. They have direct control over material inputs thanks to vertical integration, which guarantees stability in both cost and quality. Similarly, by setting up a manufacturing facility in the United States, Welspun Living diminished the purchasing power of consumers. Welspun improves margins by negotiating directly with major U.S. retailers and avoiding traditional importers by relocating closer to its major markets. Furthermore, by concentrating on the niche home textiles market, Faze Three has set itself apart and successfully reduced the threat of substitutes. Premium and specialized products encourage brand loyalty and lessen the likelihood that customers will switch. The following table neatly summarizes the strategic responses mapped to Porter's Five Forces: Company Strategic Move Porter's Force Addressed Gokaldas Exports Investment in BRFL Textiles (fabric sourcing) Lower supplier power Welspun Living U.S. manufacturing unit Lower buyer power Faze Three Focus on niche home textiles Lower substitute threat These examples show how a theoretical framework can help direct how businesses react to outside market forces. Application of Ansoff Matrix Strategies Another traditional framework that aids businesses in choosing between diversification, product development, market expansion, and market penetration is the Ansoff Matrix. These tactics are being used selectively by Indian textile exporters according to their market opportunities and competitive advantages. By entering new geographic markets like the U.S. and Europe, Indo Count and K.P.R. Mill are utilizing market development strategies. Their objective is to present current product lines—mainly clothing and bed linens—to new markets. Faze Three, meanwhile, is notable for its approach to product development. In a crowded market, it maintains the novelty and appeal of its product offerings by concentrating on cutting-edge home textile solutions, such as sustainable and functional fabrics. Welspun Living uses related diversification to combine strategies. By introducing complementary goods like pillows, it maximizes cross-selling opportunities while simultaneously strengthening its current market presence and catering to new consumer demands. This strategic mapping can be observed here: Growth Strategy Company Action Market Development Indo Count, K.P.R. Mill Expand in U.S. and Europe Product Development Faze Three Innovate niche textiles Related Diversification Welspun Living New products (pillows) in new geographies These businesses show an organized approach to growth in the face of uncertainty by adhering to Ansoff's guidelines. Focus on Risk Management With growing geopolitical tensions and protectionist policies, risk management has become a key component of textile companies' strategies. To protect their operations, businesses are identifying critical risks and constructing tactical hedges. An excellent illustration of operational risk mitigation is Welspun Living's decision to build a factory in the United States. The company safeguards itself against future tariff shocks and logistical disruptions by manufacturing within the borders of the United States. In order to improve its financial stability and withstand economic shocks, credit tightening, and rising interest rates, the company has simultaneously proactively concentrated on debt reduction. Gokaldas Exports is using vertical integration to reduce supply chain risks. By protecting its raw material sources, Gokaldas lessens its dependency on erratic outside vendors, guaranteeing availability and cost containment. The actions of these firms in response to risk factors can be captured as follows: External Factor Company Strategic Response US Tariffs Welspun Living Set up a U.S. factory to mitigate trade barriers Reduced debt to strengthen financial stability Gokaldas Exports Secured supply chain through vertical integration Even in the face of difficult macroeconomic circumstances, these risk responses guarantee long-term survival and establish a sustainable competitive advantage. Conclusion The significance of strategic thinking based on academic models is demonstrated by the example of Indian textile companies getting ready for the 2025 U.S. tariffs. Businesses are demonstrating incredible agility and foresight through the practical application of the Ansoff Matrix, Porter's Five Forces, and risk management techniques. These examples provide real-world case studies of how theoretical knowledge must change to meet changing real-world business challenges for management students and aspiring industry leaders. In today's unstable global marketplace, the capacity to foresee, innovate, and manage risk is not only a competitive advantage but also a need. As a result, the Indian textile industry, which is frequently thought of as traditional and labour-intensive, is becoming a dynamic arena for contemporary strategic management techniques. References
Time of India
01-05-2025
- Business
- Time of India
Decoding strategy blind spot: Porter's five forces for real-world startup success
In an era of startup hype and hyper-growth ambitions, many founders get swept up in building buzz and launching fast. Aggressive marketing, pitch decks, and MVP rollouts dominate early-stage focus. But amid the race to be noticed, one critical dimension is often overlooked: the strategic substance behind the business idea. Why will your venture endure once the spotlight fades? The answer lies in viewing your business not just as a product, but as a player in a larger competitive system. To thrive long term, startups must build resilient brands that align with the deeper economics of their industries. One of the most effective and timeless tools for this is Porter's Five Forces framework. Beyond the Idea: The Strategic Blind Spot in Startups Startup founders are visionaries, but vision without strategic clarity can be blinding. Many enter markets with a compelling product idea but fail to rigorously evaluate their competitive environment. Without understanding the fundamental forces at play, they often: Misjudge demand stability or pricing power. Underestimate supplier control or buyer expectations. Overlook new threats and substitute solutions. Fail to distinguish their offering in a saturated space. This lack of foresight becomes painfully clear when initial traction doesn't translate into sustainable growth. The lesson? Bold branding and speed-to-market can grab attention, but only business models aligned with the industry's structural realities will last. Porter's Five Forces: A Street-Smart Strategy Lens Harvard professor Michael E. Porter introduced his Five Forces model in 1979. Despite its academic origins, the framework remains highly applicable in today's fast-moving business world. Think of it as a street-smart diagnostic tool: it helps founders cut through the noise and ask, 'What am I really up against?' Here's a contemporary breakdown of the five forces every founder should assess: Competitive Rivalry Your direct competitors are the obvious threat, but the real insight lies in understanding how intense the fight is: Are rivals slashing prices to win customers? Is the market growing fast enough for all, or is it a zero-sum game? Are players offering unique value, or is everyone sounding the same? Founders in spaces like food delivery or consumer tech often discover too late that high rivalry and low differentiation make survival brutal. Bargaining Power of Suppliers No startup is an island. If your vendors, tech providers, or freelancers have too much control, they can: Raise prices Limit your options Dictate terms For example, relying heavily on a single cloud provider or a niche supplier with proprietary tech can give them undue leverage. Think strategically about diversification early on. Bargaining Power of Buyers Customers are king—but sometimes, they act like emperors. When buyers hold too much sway, they demand: Lower prices Faster delivery More customizations This is especially dangerous in B2B or SaaS environments where large clients may push small startups around. Founders must assess buyer dynamics to avoid being commoditized. Threat of Substitution It's not just about who else is doing what you do—it's about what else can solve the same problem. Substitutes may: Be cheaper, faster, or easier Come from outside your industry Kodak didn't just lose to other camera brands. It lost to smartphones. Substitutes sneak in sideways, so founders need wide-angle vision. Threat of New Entrants If it's easy for someone else to copy your idea, don't count on a lasting advantage. Watch out if: Entry costs are low Regulations are light Customers switch easily Barriers like strong branding, proprietary tech, and loyal communities make it harder for others to enter your space. Without these, you're always one pivot away from obsolescence. Branding Alone Won't Save You Many startups mistakenly believe that clever marketing and visual branding will outpace structural issues. But even the slickest campaigns can't hide: Unsustainable margins Overdependence on one supplier Weak customer loyalty Undifferentiated offerings Startups must treat branding as the expression of a solid strategy, not a substitute for it. From Framework to Foundation Porter's Five Forces isn't just a checklist. It's a way to ground your big idea in business reality. When used right, it empowers founders to: Build unique value propositions that go beyond hype. Spot industry risks before they derail growth. Choose battles worth fighting—and markets worth entering. Final Thought: Play to Win, Not Just to Launch In today's fast-moving world, everyone can launch. But few can last. Founders who embrace Porter's Five Forces early can design brands that don't just make noise but make money—sustainably, strategically, and smartly. That's not just good business. It's resilient branding in action. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
